TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05961813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
Study: NCT05969938

Intervention type: DIAGNOSTIC_TEST
Intervention: MRD detection
Description: Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.
Study: NCT05502835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulse pressure variation
Description: Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
Study: NCT05415397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg
Description: Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
Study: NCT05502835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional fluid management
Description: Infusion of 6 ml/kg/hr. Ringer's solution.
Study: NCT05415397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo add-on to treatment as usual (standard antidepressant treatment)
Study: NCT06580769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Implementation of a physical activity program, executed through immersive virtual reality
Study: NCT06040723

Intervention type: DEVICE
Intervention: EndoMind
Description: The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
Study: NCT05887427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilisation
Description: Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physiotherapy
Description: Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
Study: NCT06402253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music composition / edition
Description: Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch.
Study: NCT04595370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive AZD9977 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive AZD9977 as per the arms they are randomized.
Study: NCT06115317

Intervention type: OTHER
Group type: OTHER
Intervention: Prism
Description: Prism

Intervention type: OTHER
Group type: OTHER
Intervention: Prism
Description: Prism

Intervention type: OTHER
Group type: OTHER
Intervention: Sham
Description: Sham
Study: NCT04595370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive AZD9977 as per the arms they are randomized.
Study: NCT06115317

Intervention type: OTHER
Group type: OTHER
Intervention: Sham
Description: Sham
Study: NCT05231187

Intervention type: DIAGNOSTIC_TEST
Intervention: T2Resistance Panel
Description: The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)

Intervention type: DIAGNOSTIC_TEST
Intervention: T2Resistance Panel
Description: The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)

Intervention type: DIAGNOSTIC_TEST
Intervention: T2Resistance Panel
Description: The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)
Study: NCT06503900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: ACIP-CDC recommended vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: ACIP-CDC recommended vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV4 (quadrivalent inactivated influenza vaccine)
Description: ACIP recommended vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV4 (quadrivalent inactivated influenza vaccine)
Description: ACIP recommended vaccine
Study: NCT05169710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 CR 200 mg
Description: SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 CR 400 mg
Description: SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (supplied in two tablets)
Study: NCT05846022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needle
Description: Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube.
Study: NCT06073223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
Study: NCT06402253

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photography composition / edition
Description: Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch.
Study: NCT06073223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CQUPLE
Description: Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making.
Study: NCT05635812

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment and clinical scales duration: 3 hours

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment and clinical scales duration: 3 hours

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment and clinical scales duration: 3 hours

Intervention type: OTHER
Intervention: EEG experimentation
Description: duration: 1 hour

Intervention type: OTHER
Intervention: EEG experimentation
Description: duration: 1 hour

Intervention type: OTHER
Intervention: EEG experimentation
Description: duration: 1 hour

Intervention type: OTHER
Intervention: Oculometry experimentation
Description: duration: 30 minutes

Intervention type: OTHER
Intervention: Oculometry experimentation
Description: duration: 30 minutes

Intervention type: OTHER
Intervention: Oculometry experimentation
Description: duration: 30 minutes
Study: NCT05571592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo~Placebo softgel capsule formulation.
Study: NCT05138250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG
Description: participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
Study: NCT05260957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Therapy
Description: Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
Study: NCT06377605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic infiltration
Description: the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and lidocaine
Description: midazolam administration intravenous , and 5 cm lidocaine 1% infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: bupivacaine infiltration
Study: NCT05034874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXT-m200
Description: IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
Study: NCT04595370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized.
Study: NCT04569097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care lingual strengthening
Description: standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
Study: NCT04933227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
Study: NCT05765227

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Investigational silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Investigational silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Commercially available silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Commercially available silicone hydrogel multifocal contact lenses
Study: NCT05759364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Papaverine 80 mg
Description: Opium alkaloid antispasmodic drug
Study: NCT05765227

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfection system
Description: Commercially available cleaning and disinfection system for silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfection system
Description: Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
Study: NCT05185011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 10 mg TPN171H tablets，single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 10 mg TPN171H tablets，single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 10 mg TPN171H tablets，single dose
Study: NCT05124418

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: palatal masticatory mucosa thickness measurement
Description: Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
Study: NCT05030961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual team-based clinic
Description: Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual team-based clinic
Description: Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote cochlear implant programming
Description: Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
Study: NCT05034874

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05759364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04817579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital photography combined with eLABor_aid shade analyzing software
Description: ELABor_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophotometer
Description: Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional visual shade matching
Description: Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
Study: NCT06034275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP943 (QW)
Description: VIP943 will be administered by IV Infusion weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP943 (BIW)
Description: VIP943 will be administered by IV Infusion bi-weekly
Study: NCT05391763

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fascia pectoralis preservation
Description: A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fascia pectoralis preservation
Description: A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
Study: NCT05911425

Intervention type: DRUG
Group type: OTHER
Intervention: envolizumab , sovalteinib
Description: Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.